A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP

Start Date09 Mar 2026

Sponsor / Collaborator

Hangzhou Sciwind Biosciences Co., Ltd.

NCT07387094

/ Not yet recruitingPhase 3

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP

Start Date03 Mar 2026

Sponsor / Collaborator

Hangzhou Sciwind Biosciences Co., Ltd.

NCT07308184

/ Not yet recruitingPhase 3

A Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel, Phase 3 Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone

Start Date01 Dec 2025

Sponsor / Collaborator

HK inno.N Corp.

100 Clinical Results associated with Ecnoglutide

100 Translational Medicine associated with Ecnoglutide

100 Patents (Medical) associated with Ecnoglutide

Literatures (Medical) associated with Ecnoglutide

01 Oct 2025·Lancet Diabetes & Endocrinology

Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?

Article

Author: Scheen, André J

01 Oct 2025·Lancet Diabetes & Endocrinology

Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial

Article

Author: Han, Jie ; Li, Qingju ; Guo, Mengying ; Cheng, Zhifeng ; Pan, Hai ; Zheng, Qing ; Zhou, Yanqin ; Wang, Huihui ; Zhu, Yikun ; Yang, Ming ; Li, Feng ; Guan, Lei ; Wu, Jun ; Ning, Jing ; Zhao, Shuping ; Duan, Binhong ; Shi, Xiaoguang ; Jiang, Feifei ; Mi, Nianrong ; Li, Xiaoying ; He, Yang ; Bing, Shaohui ; Yang, Liu ; Wang, Xin ; Li, Yao ; Guo, Wanjun ; Wang, Su ; Ling, Hongwei ; Xue, Haibo ; Wang, Haifang ; Bu, Yue

BACKGROUND:

Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.

METHODS:

We conducted a 52-week, open-label, active-controlled, phase 3 trial at 52 hospitals in China. Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included. Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly. The primary endpoint was mean change from baseline in HbA_1c at week 32 (non-inferiority for ecnoglutide 0·6 mg and 1·2 mg, with a 0·4% non-inferiority margin; superiority for ecnoglutide 1·2 mg) and was assessed in all randomly assigned participants who received at least one dose of study treatment (full analysis set). Safety was assessed in all randomly assigned participants who received at least one dose of study drug and had at least one safety evaluation after starting treatment. This trial is registered with ClinicalTrials.gov (NCT05680129) and has ended.

FINDINGS:

Between Jan 10 and May 30, 2023, 623 participants were randomly assigned, of whom 621 comprised the full analysis set (mean age 53·9 years [SD 10·1], 347 [56%] males, 274 [44%] females, and mean HbA_1c 8·40% [SD 0·78]; 68·28 mmol/mol [8·56]; 206 in the ecnoglutide 0·6 mg group, 208 in the ecnoglutide 1·2 mg group, and 207 in the dulaglutide 1·5 mg group). At week 32, mean HbA_1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg, 1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide. Estimated treatment differences versus dulaglutide were -0·26% (95% CI -0·39 to -0·13; -2·84 mmol/mol [-4·29 to -1·38]) with ecnoglutide 0·6 mg and -0·24% (-0·38 to -0·11; -2·67 mmol/mol [-4·14 to -1·20]; p=0·0002 for superiority) with ecnoglutide 1·2 mg. HbA_1c reductions were sustained to week 52. During the 52 weeks, six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events.

INTERPRETATION:

Once-weekly ecnoglutide 0·6 mg and 1·2 mg were non-inferior to dulaglutide 1·5 mg in reducing HbA_1c in adults with type 2 diabetes and elevated glucose concentrations on metformin monotherapy. Although the 1·2 mg dose showed statistically significantly greater reductions in HbA_1c from baseline to week 32 than dulaglutide 1·5 mg, the difference was not considered clinically relevant. Both doses of ecnoglutide were well tolerated. These results suggest that ecnoglutide might offer a new treatment option for type 2 diabetes.

FUNDING:

Hangzhou Sciwind Biosciences.

01 Sep 2025·Lancet Diabetes & Endocrinology

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Article

Author: Wen, Binhong ; Guo, Mengying ; Guo, Tonglan ; Fu, Wenyan ; Tian, Junhang ; Zheng, Qing ; Yang, Ming ; Pan, Hai ; Lian, Qiufang ; Gao, Leili ; Gao, Ge ; Zhang, Yawei ; Ning, Jing ; Wang, Haifang ; Shi, Bimin ; Hu, Wen ; Wang, Kun ; Shi, Xiaoguang ; Ji, Linong ; Xing, Ying ; Li, Ya ; Lu, Yibing ; Li, Yao ; Huang, Chongbing ; Han, Jie ; Li, Qingju ; Jiang, Hongwei ; Yuan, Mingxia ; Xue, Haibo

BACKGROUND:

Ecnoglutide is a novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist currently in development for weight management. We aimed to assess the efficacy and safety of once weekly ecnoglutide versus placebo for the treatment of overweight or obesity in Chinese adults.

METHODS:

This randomised, double-blind, placebo-controlled, phase 3 trial was done at 36 medical centres across China. Eligible adults were aged 18-75 years with overweight or obesity (defined as BMI ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity [prediabetes, hypertension, hyperlipidaemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea syndrome, or weight-bearing joint pain]), without diabetes (type 1 or 2). Participants were randomly assigned (3:3:3:1:1:1) via computer-generated random sequencing to receive subcutaneous ecnoglutide (1·2, 1·8, or 2·4 mg) or volume-matched placebo (1·2, 1·8, or 2·4 mg), once weekly, stratified by BMI at screening (≥28 kg/m² and <28 kg/m²). The coprimary endpoints were percentage change in bodyweight and proportion of participants with a reduction in bodyweight of 5% or more at week 40 (using the treatment policy estimand in the full analysis set). The full analysis set included all randomly assigned participants who were exposed to at least one dose of study drug or placebo according to their assigned treatment group. Safety was assessed in all participants who received at least one dose and had a safety assessment after medication. This study was registered with ClinicalTrials.gov, NCT05813795, and is complete.

FINDINGS:

Between April 5, 2023, and June 20, 2024, 882 participants were screened and 664 were randomly assigned to receive ecnoglutide 1·2 mg (n=166), ecnoglutide 1·8 mg (n=166), ecnoglutide 2·4 mg (n=167), or placebo (n=165). At week 40, the least-squares mean percentage change in bodyweight was -9·1% (SE 0·8) in the ecnoglutide 1·2 mg group, -10·9% (0·9) in the ecnoglutide 1·8 mg group, and -13·2% (0·8) in the ecnoglutide 2·4 mg group versus 0·1% (0·8) in the placebo group, and the respective estimated treatment differences compared with placebo were -9·2% (97% CI -11·0 to -7·5), -11·1% (-13·1 to -9·1), and -13·3% (-15·3 to -11·3), respectively (all p<0·0001). The proportion of participants who achieved at least a 5% reduction in bodyweight at week 40 was 77% in the ecnoglutide 1·2 mg group, 84% in the ecnoglutide 1·8 mg group, and 87% in the ecnoglutide 2·4 mg group versus 16% of participants in the placebo group, and the respective estimated treatment differences versus placebo were 60% (98% CI 50 to 71), 68% (58 to 78), and 70% (61 to 80; all p<0·0001). Treatment-emergent adverse events were observed in 155 (93%) of 166 participants in the ecnoglutide 1·2 mg group, 154 (93%) of 166 participants in the ecnoglutide 1·8 mg group, 156 (93%) of 167 participants in the ecnoglutide 2·4 mg group, and 139 (84%) of 165 participants in the placebo group. The most common adverse events were mild-to-moderate gastrointestinal related events. Ten participants treated with ecnoglutide discontinued treatment due to adverse events.

INTERPRETATION:

In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.

FUNDING:

Hangzhou Sciwind Biosciences.

News (Medical) associated with Ecnoglutide

06 Mar 2026

·www.prnewswire.com

Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management

HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved Ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. Ecnoglutide injection is the world's first approved cAMP-biased GLP-1RA for weight management. Through its unique biased mechanism, it achieves highly effective weight reduction in the Chinese population, with an average 15.1% placebo-adjusted weight loss, and 92.8% of patients reaching clinical meaningful weight loss. This marks a breakthrough in the field of weight management, and provides a precise new pathway for scientific, long‑acting and healthy weight loss. Biased Mechanism for More Effective and Healthier Weight Loss Based on the globally pioneering cAMP-biased GLP-1 receptor agonism mechanism, Ecnoglutide injection selectively activates the cAMP signaling pathway and minimizes β-arrestin recruitment, distinguishing it from conventional non-biased GLP-1RAs. This mechanism delivers potent and sustained weight loss with no obvious plateau phase, and supports concurrent improvement in metabolism and reduced chronic disease risk alongside weight reduction, perfectly aligning with the core goals of healthy weight management. The Phase 3 clinical trial results of Ecnoglutide injection were formally published in The Lancet Diabetes & Endocrinology in June 2025, and were further highlighted in a special report by Nature. Its clinical findings have also been oral presented at the American Diabetes Association (ADA) Scientific Sessions and the Annual Meeting of the European Association for the Study of Diabetes (EASD), underscoring its innovative value in weight management. 15.1% Weight Loss at 48 Weeks: Sustained Effect, No Plateau and Comprehensive Benefits The approval of Ecnoglutide injection for weight management is supported by the Phase 3 clinical trial (SLIMMER) conducted in Chinese adults with overweight or obesity. Using the treatment policy estimand, at week 48, Ecnoglutide demonstrated dose-dependent weight loss, with the highest dose (2.4 mg) achieving a mean 15.4% (placebo-adjusted 15.1%) reduction from baseline and 92.8% of participants achieving clinically meaningful ≥5% weight loss - nearly seven times the placebo response rate. Notably, 79.6% and 63.5% of participants achieved ≥10% and ≥15% weight reduction, respectively, numerically exceeding results seen with other unbiased GLP-1 therapies in similar populations. Patients in the Ecnoglutide groups continued to have weight loss at week 48 without reaching a plateau, indicating that even greater weight loss might be achievable with extended Ecnoglutide treatment. Accompanied by clinically meaningful weight loss, Ecnoglutide treatment significantly improved other key cardiometabolic risk factors (including waist circumference, blood pressure, lipid profile, HbA1c, fasting glucose, insulin level, and HOMA-IR) along with a notable reduction in uric acid levels, up to 54.3 µmol/L, and lower hyperuricaemia incidence. In addition, Ecnoglutide significantly reduced liver fat content. Among participants with a baseline liver fat content ≥ 8%, the mean percentage change from baseline in liver fat content at week 40 reached -53.1% in the Ecnoglutide 2.4 mg group. Furthermore, all Ecnoglutide doses demonstrated significantly greater reductions in liver enzyme concentrations compared to the placebo group. "As the world's first approved biased GLP‑1 receptor agonist, Ecnoglutide demonstrated the most pronounced weight‑loss efficacy in the SLIMMER study among all GLP‑1 receptor agonist trials for weight management conducted in China to date. " said Dr. Linong Ji, Principal Investigator of the SLIMMER trial. " Following 48 weeks of treatment, the Ecnoglutide group achieved a 15.4% reduction in body weight, and 92.8% of patients attained clinically meaningful weight loss. Given its superior efficacy, Ecnoglutide will provide a more potent treatment option for individuals in China with weight‑management needs upon approval." "The approval of Ecnoglutide injection for weight management is an important milestone for Sciwind in the metabolic disease area, and a breakthrough for China‑innovated drugs in the global GLP‑1 field. As the world's first approved cAMP‑biased GLP‑1 receptor agonist, Ecnoglutide injection has now completed its strategic positioning for both weight management and type 2 diabetes indications. Sciwind is committed to delivering innovative therapies with robust weight loss and superior metabolic benefits to address long-unmet medical needs, providing a safer, more scientific and sustainable treatment option for patients with overweight and obesity in China and globally." Said Dr. Hai Pan, the Founder and CEO of Sciwind Biosciences. About Overweight and Obesity The prevalence of overweight and obesity in China continues to rise. As an independent chronic disease and a major risk factor for multiple comorbidities, obesity has become a major public health issue and the sixth leading risk factor for death and disability in China. Obesity represents a multifaceted health challenge with far-reaching implications across multiple organ systems. Obesity related diseases encompass a broad spectrum of conditions including cardiovascular disease, T2DM, MASH, OSA and numerous other comorbidities. Lifestyle intervention remains the cornerstone of overweight and obesity management. When lifestyle modifications alone fail to achieve weight loss goals, pharmacotherapy may be used as combination treatment. About Ecnoglutide Ecnoglutide injection, originally discovered and developed by Sciwind Biosciences, is the world's first approved cAMP-biased GLP-1 receptor agonist enhancing clinical efficacy and accessibility. Ecnoglutide injection has currently been approved for two indications in China: adult weight management with overweight or obesity and the treatment of adult type 2 diabetes. From Phase I through Phase III, Ecnoglutide injection has consistently demonstrated a favorable safety profile and strong efficacy, with the findings published in leading metabolic journals, underscoring its potential as a promising therapy for patients with metabolic diseases. About Sciwind Biosciences Sciwind Biosciences is a commercial-stage biopharmaceutical company, dedicated to addressing the unmet medical needs in the field of weight management and metabolic diseases. Sciwind has established a robust pipeline anchored by the lead asset, Ecnoglutide (XW003). It has developed multiple proprietary technology platforms, including biased agonist discovery platform, long-acting and oral peptide delivery platforms, and has identified a series of drug candidates based on these core technology platforms. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic pathways, offering both injectable and oral treatment solutions to deliver sustainable and high-quality therapies for patients with metabolic diseases. For more information, please visit . SOURCE Sciwind Biosciences Co., Ltd. 21% more press release views with Request a Demo

Clinical ResultDrug ApprovalPhase 3Phase 2

06 Mar 2026

·www.biopharmadive.com

Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs

Today, a brief rundown of news from Pfizer and Alnylam Pharmaceuticals, as well as updates from Helus Pharma and Daiichi Sankyo that you may have missed.Pfizer has won its first obesity drug approval, announcing Friday that Chinese regulators have cleared a medicine the company recently acquired partial rights to in a licensing deal. According to Pfizer, Chinas health authorities greenlitSeverwin, formerly ecnoglutide, for weight management in adults. Pfizer last month acquired from Sciwind Biosciences exclusive commercialization rights to the drug in China, where it had already been OKd for Type 2 diabetes. That deal was one of a series of obesity-related investments for Pfizer, which paid $10 billion for Metsera last year and reached a potentially $2 billion licensing deal with YaoPharma. Ben FidlerTenaya Therapeutics and Alnylam Pharmaceuticals will work together to unearth up to 15 new genetic targets that could be used to develop treatments for heart disease. Under the deal announced Thursday, Tenaya will be responsible for validating the targets and, in return, receive up to $10 million upfront and possibly $1.13 billion more should the research eventually yield approved medicines. Alnylam, meanwhile, will handle development and commercialization costs. In a note to clients Thursday, William Blair analyst Andy Hsieh wrote that the upfront payouts due to Tenayacould be cut by up to $4 million if the targets it finds dont meet certain technical standards and arent advanced. Delilah AlvaradoHelus Pharma on Thursday reported results from a mid-stage signal detection study in people with generalized anxiety disorder. Helus said a regimen involving its therapy HLP004 on top of standard care was associated with a clinically meaningful 10-point improvement on a scale evaluating anxiety symptoms after six weeks.There were no drug-related serious adverse events either, and the company claimed the results were encouraging enough to support continued development. Still, company shares lost more than a quarter of their value, falling to their lowest trading levels in almost a year. Ben FidlerDaiichi Sankyo reached a deal for rights to a digital therapeutic GAIA is developing for people with high cholesterol. The partnership announced Thursday involves whats called lipodia, an app that uses AI-powered cognitive behavioral therapy to help patients adopt positive lifestyle changes and health habits. The alliance initially involves only Germany but could expand to involve all major markets in Europe. Lipodia is currently in late-stage clinical testing. Ben Fidler '

License out/inDrug Approval

26 Feb 2026

·www.biospace.com

Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy

iStock, Hwangdaesung Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics’ liver-directed gene editor. Almost exactly a year ago to the day, Pfizer withdrew the hemophilia B gene therapy Beqvez from the market and ended all work on it. Now, the pharma wants back in the genetics game, inking a global gene editing pact with Beam Therapeutics. Details of the deal, announced in Beam’s fourth-quarter earnings report on Tuesday, were scant. The companies did not reveal how much Pfizer is paying upfront, nor did they specify milestone values. It also remains unclear what disease the pharma plans to go after, though the partners did say the gene editor under license is a liver-targeted therapy. Pfizer informed Beam of its decision to move forward with the candidate in December 2025, according to Tuesday’s release, upon the completion of a four-year research partnership. The companies first came together in January 2022, with a $300 million upfront payment from Pfizer and the potential of $1.05 billion in milestones. Pfizer will have exclusive global rights to Beam’s editor. The pharma will take charge of all clinical development activities worldwide, as well as work toward regulatory approvals and set up manufacturing and commercialization networks, Beam said. Aside from milestones, Beam will have the option, at the end of Phase 1/2 development, to opt in to the editor’s subsequent development. If the biotech chooses to participate, it will shoulder 35% of the costs and get 35% of net profits, while the remainder will fall to Pfizer. The Beam bet represents an about-face for Pfizer, which in January 2025 abandoned the hemophilia B gene therapy Beqvez, pulling it from shelves across the world and ending all related development work. At the time, the pharma said it was pulling back given “limited interest patients and their doctors have demonstrated in hemophilia gene therapies.” Gene therapy Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy. February 21, 2025 · 2 min read · Tristan Manalac Since then, Pfizer hasn’t taken any steps to replenish its gene therapy pipeline. The pharma has, however, been a very proactive dealmaker in other markets. Most notably, Pfizer came out on top of a messy bidding war with Novo Nordisk over obesity startup Metsera, ultimately paying aorund $10 billion . Shortly after, the pharma bet up to $1.9 billion to partner with China’s YaoPharma for a GLP-1 drug. Earlier this week, Pfizer took another China trip and picked up a commercial GLP-1 injection called ecnoglutide from Sciwind Biosciences, paying up to $495 million.

Gene TherapyLicense out/in

100 Deals associated with Ecnoglutide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	China	Hangzhou Sciwind Biosciences Co., Ltd.	03 Mar 2026
Overweight	China	Hangzhou Sciwind Biosciences Co., Ltd.	03 Mar 2026
Diabetes Mellitus, Type 2	China	Hangzhou Sciwind Biosciences Co., Ltd.	27 Jan 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 3	China	Hangzhou Sciwind Biosciences Co., Ltd.	02 Feb 2026
Metabolic Dysfunction Associated Steatohepatitis	Phase 1	China	Hangzhou Sciwind Biosciences Co., Ltd.	16 Jun 2021
Alzheimer Disease	Preclinical	China	Hangzhou Sciwind Biosciences Co., Ltd.	19 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05680155 (EECOH-1, Pubmed \| Nat Commun) Manual	Phase 3	Diabetes Mellitus, Type 2	211	Ecnoglutide 0.6 mg	rujzdilajz(tecqhdquod) = qocxyeshab vhmvkdlxxa (dmoetanoau, -2.18 to -1.73) Met View more	Positive	07 Jan 2026
				Ecnoglutide 1.2 mg	rujzdilajz(tecqhdquod) = ctopxwrvos vhmvkdlxxa (dmoetanoau, -2.65 to -2.20) Met View more
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	qiymstlqjy(zyjyqikgfg) = tjwsfptpoh shybatemls (yygppdbdpv ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	qiymstlqjy(zyjyqikgfg) = arqjgsjgxn shybatemls (yygppdbdpv ) View more
NEWS Manual	Phase 3	Obesity	-	ecnoglutide	nwpgutlolu(xyhhltoixp) = nuigldpopo wxeqjnpwby (tgkztffpvg )	Positive	27 Jun 2025
NCT05813795 (SLIMMER, Lancet \| NEWS 1 \| NEWS 2 \| NEWS 3) Manual	Phase 3	Overweight \| Obesity	664	ecnoglutide 1.2 mg	sxgqrzrddg(fffifnorfg) = ffycslyjca cadlgaqrlc (lzrmanrdfg, 0.8) View more	Positive	21 Jun 2025
				ecnoglutide 1.8 mg	sxgqrzrddg(fffifnorfg) = fokqfdfgbb cadlgaqrlc (lzrmanrdfg, 0.9) View more
CTR20211014 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	145	Ecnoglutide 0.4 mg	trfwfxwdul(npfnituuhg) = axcbvcludo fagdejcjwt (jvswimitkg ) View more	Positive	27 Sep 2024
				Ecnoglutide 0.8 mg	trfwfxwdul(npfnituuhg) = qwwqwqbxlh fagdejcjwt (jvswimitkg )
NCT05184322 (ADA2024) Manual	Phase 1	Obesity	56	Oral Ecnoglutide 7mg (healthy)	xxvekzwlgl(cpuuojqvxc) = The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. tadkffgdcv (mnrbwbcdao ) View more	Positive	21 Jun 2024
				Oral Ecnoglutide 15mg (healthy)
NCT05680155 (ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 2	211	Ecnoglutide 0.6 mg	xkcyonllev(nsvnzbmdic) = dhojvivayb iwrokjlohz (fkbqalkvdg ) View more	Positive	21 Jun 2024
				Ecnoglutide 1.2 mg	xkcyonllev(nsvnzbmdic) = bcvdktmlwd iwrokjlohz (fkbqalkvdg ) View more
NEWS Manual	Phase 1	Obesity	56	ecnoglutide	isguejgwur(aeskdbarvo) = 最常见的不良事件包括恶心、头痛、腹泻、呕吐和食欲减退，大多数不良事件的严重程度为轻中度，主要发生在剂量递增期 ozjagqbimp (yetuzzbgso )	Positive	24 Jan 2024
				placebo
NCT05680155 (NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	211	Ecnoglutide 0.6 mg	bqfuighrhk(mbdoqsvqkr) = xclprjwtna kekirdqpzi (sssjgrhhnf ) View more	Positive	03 Jan 2024
				Ecnoglutide 1.2 mgEcnoglutide 1.2 mg	bqfuighrhk(mbdoqsvqkr) = rttsvomaox kekirdqpzi (sssjgrhhnf ) View more
CTR20211014 (ADA 12023 \| ADA 22023) Manual	Phase 2	Diabetes Mellitus, Type 2	145	XW003 0.4 mg	lfskiiuzlp(zwmmesaoil) = rddqbrvqgu rweaeuzaum (ndtntbogue ) View more	Positive	20 Jun 2023
				XW003 0.8 mg	lfskiiuzlp(zwmmesaoil) = fokkozajxf rweaeuzaum (ndtntbogue ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis